Pre-Exposure Vaccination Associated With Reduced Mpox Disease Severity In Cisgender Men And Boys, Study Finds

Infectious Disease Advisor (7/25, Nye) reported a study found that “the administration of the modified vaccinia virus Ankara vaccine (JYNNEOS®) prior to mpox exposure is associated with reduced disease severity in cisgender men and boys.” The article added “In an analysis of severe mpox outcomes, pre-exposure vaccination was associated with protection against hospital admission, chills, fever, and lymphadenopathy. In contrast, post-exposure vaccination was only associated with protection against illness involving chills.” They concluded, “Securing high uptake of JYNNEOS is an important public health objective to mitigate [mpox virus] transmission and to lower individuals’ risk of severe disease if they are exposed to [mpox virus].” The study was published in The Lancet Infectious Diseases.